Main menu button

Kancera AB

Since its founding in 2010, Kancera has worked with the development of small molecule drug candidates for inflammatory diseases and cancer. The company conducts clinical development in myocardial infarction.

Initiation of coverage: 24 October 2022
Sector: Healthcare
List: Nasdaq First North
Ticker: KAN:SS
Niklas Elmhammer
Niklas Elmhammer LinkedIn
Senior Equity Analyst